Accès gratuit
Med Sci (Paris)
Volume 20, Numéro 4, Avril 2004
Page(s) 402 - 407
Section M/S revues
Publié en ligne 15 avril 2004
  1. A consensus document of the Joint European society of cardiology/American college of cardiology committee for the redefinition of myocardial infarction. Eur Heart J 2000; 21 : 1502–13. [Google Scholar]
  2. ISIS 2 (second international study of infarct survival) collaborative group. Randomised trial of intravenous streptokinase, oral aspirin, both or neither among 17,187 cases of suspected acute myocardial infarction : ISIS 2. Lancet 1988; 2 : 349–60. [Google Scholar]
  3. The GUSTO investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329 : 673–82. [Google Scholar]
  4. The GUSTO IIb angioplasty substudy investigators. A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. N Engl J Med 1997; 336 : 1621–8. [Google Scholar]
  5. Bonnefoy E, Lapostolle F, Leizorovicz A, et al. On behalf of the CAPTIM study group. Primary angioplasty versus prehospital fibrinolysis in acute myocardial infarction : a randomised study. Lancet 2002; 360 : 825–9. [Google Scholar]
  6. Every NR, Parisons LS, Hlatky M, et al. For the myocardial infarction triage and intervention investigators. A comparison of thrombolytic therapy with primary coronary angioplasty for acute myocardial infarction. N Engl J Med 1996; 335 : 1253–60. [Google Scholar]
  7. Danchin N, Vaur L, Genès N, et al. Treatment of acute myocardial infarction by primary coronary angioplasty or intravenous thrombolysis in the « real world » : one-year results from a nation-wide French survey. Circulation 1999; 99 : 2639–44. [Google Scholar]
  8. Freemantle N, Cleland J, Young P, et al. Beta-blockade after myocardial infarction : systematic review and metaregression analysis. Br Med J 1999; 318 : 1730–7. [Google Scholar]
  9. ISIS-4 (fourth international study of infarct survival) collaborative group. ISIS-4 : a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet 1995; 345 : 669–85. [Google Scholar]
  10. Gruppo Italiano per lo studio della sopravvivenza nell’infarto miocardico. GISSI-3 : effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994; 343 : 1115–22. [Google Scholar]
  11. Braunwald E. Unstable angina. A classification. Circulation 1989; 80 : 410–4. [Google Scholar]
  12. Boersma E, Pieper KS, Steyerberg EW, et al. Predictors of outcome in patients with acute coronary syndromes without ST segment elevation : Results from an international trial of 9,461 patients. Circulation 2000; 101 : 2557–67. [Google Scholar]
  13. White HD, Wong CK. Risk stratification and treatment benefits in patients with non-ST-elevation acute myocardial infarction. Eur Heart J 2002; 23 : 187–91. [Google Scholar]
  14. Antman EM, Cohen M, Bernink PJLM, et al. The TIMI risk score for unstable angina/non ST elevation MI. A method for prognostication and therapeutic decision making. JAMA 2000; 284 : 835–42. [Google Scholar]
  15. Kaul P, Fu Y, Chang WC, et al. Prognostic value of ST segment depression in acute coronary syndromes : insights from PARAGON-A applied to GUSTO-IIb. J Am Coll Cardiol 2001; 38 : 64–71. [Google Scholar]
  16. Jernberg T, Lindahl B, Wallentin L. The combination of a continuous 12-lead ECG and troponin T. A valuable tool for risk stratification during the first 6 hours in patients with chest pain and a non-diagnostic ECG. Eur Heart J 2000; 21 : 1464–72. [Google Scholar]
  17. Heindrich PA, Alloggiamento T, Melsop K, et al. The prognostic value of troponin in patients with non-ST elevation acute coronary syndromes : a meta-analysis. J Am Coll Cardiol 2001; 38 : 478–85. [Google Scholar]
  18. De Lemos JA, Morrow DA, Bentley JH, et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 2001; 345 : 1014–21. [Google Scholar]
  19. Morrow DA, Antman EM, Snapinn SM, et al. An integrated clinical approach to predicting the benefit of tirofiban in non-ST elevation acute coronary syndromes : application of the TIMI risk score for UA/NSTEMI in PRISM-plus. Eur Heart J 2002; 23 : 223–9. [Google Scholar]
  20. Savonitto S, Ardissino D, Granger CB, et al. Prognostic value of the admission electrocardiogram in acute coronary syndromes. JAMA 1999; 281 : 707–13. [Google Scholar]
  21. Boersma E, Harrington RA, Moliterno DJ, et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes : a meta-analysis of all major randomised clinical trials. Lancet 2002; 359 : 189–98. [Google Scholar]
  22. The clopidogrel in unstable angina to prevent recurrent events trial investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345 : 494–502. [Google Scholar]
  23. Fragmin and fast revascularisation during instability in coronary artery disease investigators. Invasive compared with non-invasive treatment in unstable coronary-artery disease : FRISC II prospective randomised multicentre study. Lancet 1999; 354 : 708–15. [Google Scholar]
  24. Cannon CP, Weintraub WS, Demopoulos LA, et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001;344 : 1879–87. [Google Scholar]
  25. Fox KAA, Poole-Wilson PA, Henderson RA, et al. For the RITA investigators. Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction : the British heart foundation RITA 3 randomised trial. Lancet 2002; 360 : 743–51. [Google Scholar]
  26. Bertrand ME, Simoons ML, Fox KAA, et al. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. The Task force on the management of acute coronary syndromes of the European society of cardiology. Eur Heart J 2002; 23 : 1809–40. [Google Scholar]
  27. Antithrombotic trialists’ collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high risk patients. Br Med J 2002; 324 : 71–86. [Google Scholar]
  28. The Scandinavian simvastatin survival study group. Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease : the Scandinavian simvastatin survival study (4S). Lancet 1994; 344 : 1383–9. [Google Scholar]
  29. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators. N Engl J Med 1996; 335 : 1001–9. [Google Scholar]
  30. Heart protection study collaborative group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals : a randomised placebo-controlled trial. Lancet 2002; 360 : 7–22. [Google Scholar]
  31. The heart outcomes prevention evaluation study investigators. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342 : 145–53. [Google Scholar]
  32. The Europa trial : design, baseline demography and status of the substudies. Cardiovasc Drugs Ther 2001; 15 : 169–79. [Google Scholar]
  33. Pitt B, Waters D, Brown WV, et al. For the atorvastatin versus revascularization treatment investigators. Aggressive lipid lowering therapy compared with angioplasty in stable coronary artery disease. N Engl J Med 1999; 341 : 70–6. [Google Scholar]
  34. Steinhubl SR, Berger PB, Mann JT, et al. For the CREDO investigators. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention. A randomized controlled trial. JAMA 2002; 288 : 2411–20. [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.